350 related articles for article (PubMed ID: 27376689)
1. Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition.
Hohmann AF; Martin LJ; Minder JL; Roe JS; Shi J; Steurer S; Bader G; McConnell D; Pearson M; Gerstberger T; Gottschamel T; Thompson D; Suzuki Y; Koegl M; Vakoc CR
Nat Chem Biol; 2016 Sep; 12(9):672-9. PubMed ID: 27376689
[TBL] [Abstract][Full Text] [Related]
2. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.
Martin LJ; Koegl M; Bader G; Cockcroft XL; Fedorov O; Fiegen D; Gerstberger T; Hofmann MH; Hohmann AF; Kessler D; Knapp S; Knesl P; Kornigg S; Müller S; Nar H; Rogers C; Rumpel K; Schaaf O; Steurer S; Tallant C; Vakoc CR; Zeeb M; Zoephel A; Pearson M; Boehmelt G; McConnell D
J Med Chem; 2016 May; 59(10):4462-75. PubMed ID: 26914985
[TBL] [Abstract][Full Text] [Related]
3. BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma.
Weisberg E; Chowdhury B; Meng C; Case AE; Ni W; Garg S; Sattler M; Azab AK; Sun J; Muz B; Sanchez D; Toure A; Stone RM; Galinsky I; Winer E; Gleim S; Gkountela S; Kedves A; Harrington E; Abrams T; Zoller T; Vaupel A; Manley P; Faller M; Chung B; Chen X; Busenhart P; Stephan C; Calkins K; Bonenfant D; Thoma CR; Forrester W; Griffin JD
Blood Cancer J; 2022 Jul; 12(7):110. PubMed ID: 35853853
[TBL] [Abstract][Full Text] [Related]
4. The ncBAF Complex Regulates Transcription in AML Through H3K27ac Sensing by BRD9.
Klein DC; Lardo SM; Hainer SJ
Cancer Res Commun; 2024 Jan; 4(1):237-252. PubMed ID: 38126767
[TBL] [Abstract][Full Text] [Related]
5. BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition.
Del Gaudio N; Di Costanzo A; Liu NQ; Conte L; Migliaccio A; Vermeulen M; Martens JHA; Stunnenberg HG; Nebbioso A; Altucci L
Cell Death Dis; 2019 Apr; 10(5):338. PubMed ID: 31000698
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of imidazo[1,5-a]pyrazin-8(7H)-one derivatives as BRD9 inhibitors.
Zheng P; Zhang J; Ma H; Yuan X; Chen P; Zhou J; Zhang H
Bioorg Med Chem; 2019 Apr; 27(7):1391-1404. PubMed ID: 30824168
[TBL] [Abstract][Full Text] [Related]
7. 3-Hydroxyisoindolin-1-one derivates: Synthesis by palladium-catalyzed CH activation as BRD4 inhibitors against human acute myeloid leukemia (AML) cells.
Chen P; Yang Y; Yang L; Tian J; Zhang F; Zhou J; Zhang H
Bioorg Chem; 2019 May; 86():119-125. PubMed ID: 30690335
[TBL] [Abstract][Full Text] [Related]
8. Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade.
Yuan T; Qi B; Jiang Z; Dong W; Zhong L; Bai L; Tong R; Yu J; Shi J
Eur J Med Chem; 2019 Sep; 178():468-483. PubMed ID: 31207462
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological activity evaluation of a series of novel sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia.
Feng Z; Chen A; Shi J; Zhou D; Shi W; Qiu Q; Liu X; Huang W; Li J; Qian H; Zhang W
Bioorg Chem; 2021 Jun; 111():104849. PubMed ID: 33798846
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic modulation by targeting bromodomain containing protein 9 (BRD9): Its therapeutic potential and selective inhibition.
Ali MM; Naz S; Ashraf S; Knapp S; Ul-Haq Z
Int J Biol Macromol; 2023 Mar; 230():123428. PubMed ID: 36709803
[TBL] [Abstract][Full Text] [Related]
11. Research progress of selective small molecule bromodomain-containing protein 9 inhibitors.
Hui M; Jian Z; Peiyuan Z; Zhenwei W; Huibin Z
Future Med Chem; 2018 Apr; 10(8):895-906. PubMed ID: 29620420
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance.
Crawford TD; Vartanian S; Côté A; Bellon S; Duplessis M; Flynn EM; Hewitt M; Huang HR; Kiefer JR; Murray J; Nasveschuk CG; Pardo E; Romero FA; Sandy P; Tang Y; Taylor AM; Tsui V; Wang J; Wang S; Zawadzke L; Albrecht BK; Magnuson SR; Cochran AG; Stokoe D
Bioorg Med Chem Lett; 2017 Aug; 27(15):3534-3541. PubMed ID: 28606761
[TBL] [Abstract][Full Text] [Related]
13. Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands.
Remillard D; Buckley DL; Paulk J; Brien GL; Sonnett M; Seo HS; Dastjerdi S; Wühr M; Dhe-Paganon S; Armstrong SA; Bradner JE
Angew Chem Int Ed Engl; 2017 May; 56(21):5738-5743. PubMed ID: 28418626
[TBL] [Abstract][Full Text] [Related]
14. Drug-like biimidazole derivatives dually target c-MYC/BCL-2 G-quadruplexes and inhibit acute myeloid leukemia.
Hu MH; Yu BY; Wang X; Jin G
Bioorg Chem; 2020 Nov; 104():104264. PubMed ID: 32920366
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.
Herrmann H; Blatt K; Shi J; Gleixner KV; Cerny-Reiterer S; Müllauer L; Vakoc CR; Sperr WR; Horny HP; Bradner JE; Zuber J; Valent P
Oncotarget; 2012 Dec; 3(12):1588-99. PubMed ID: 23249862
[TBL] [Abstract][Full Text] [Related]
16. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Zuber J; Shi J; Wang E; Rappaport AR; Herrmann H; Sison EA; Magoon D; Qi J; Blatt K; Wunderlich M; Taylor MJ; Johns C; Chicas A; Mulloy JC; Kogan SC; Brown P; Valent P; Bradner JE; Lowe SW; Vakoc CR
Nature; 2011 Aug; 478(7370):524-8. PubMed ID: 21814200
[TBL] [Abstract][Full Text] [Related]
17. BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors.
Krämer KF; Moreno N; Frühwald MC; Kerl K
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28714904
[TBL] [Abstract][Full Text] [Related]
18. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
19. Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.
Theodoulou NH; Bamborough P; Bannister AJ; Becher I; Bit RA; Che KH; Chung CW; Dittmann A; Drewes G; Drewry DH; Gordon L; Grandi P; Leveridge M; Lindon M; Michon AM; Molnar J; Robson SC; Tomkinson NC; Kouzarides T; Prinjha RK; Humphreys PG
J Med Chem; 2016 Feb; 59(4):1425-39. PubMed ID: 25856009
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic and pharmacological control of pigmentation via Bromodomain Protein 9 (BRD9).
Basuroy T; Dreier M; Baum C; Blomquist T; Trumbly R; Filipp FV; de la Serna IL
Pigment Cell Melanoma Res; 2023 Jan; 36(1):19-32. PubMed ID: 36112085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]